Protein–protein interaction disruptor molecules that displace PDE6d from KRAS by binding to the prenyl‐binding pocket of the PDE proved to be effective in inhibiting oncogenic KRAS signaling and showed some efficacy in models of pancreatic cancer at micromolar concentrations [33]. Here, KRAS is linked to familial pancreatic carcinoma.